NEW YORK (GenomeWeb) — IntegraGen announced today that it is collaborating with investigators from the FIRE-3 clinical trial to study the use of a microRNA biomarker to predict clinical outcomes in metastatic colorectal cancer patients treated with anti-EGFR therapies.

The FIRE-3 study is a Phase III trial comparing FOLFIRI — Camptosar (irinotecan) with fluorouracil and folinic acid — in combination with either Erbitux (cetuximab) or Avastin (bevacizumab) as a first-line therapy in patients with KRAS exon 2 wild-type stage IV colorectal cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.